PORTON | 20th

Enabling the Public’ s Early Access to Good Medicines

NEWSLETTER

March 2025

Porton Pharma Solutions Ltd.

Contents

Technical Enabling

Facilitating PROTAC Drugs Development with Innovative Processes

Porton has extensive experience in research and manufacturing services, particularly in the field of PROTAC drug development. We've participated in the development of over ten PROTAC projects for various global clients, providing comprehensive, reliable, rapid, compliant, and one-stop services.

Read more



Preformulation Strategy- Inception to Completion

Drug discovery is an exceedingly complex process.

Once a new molecule is discovered, different physicochemical properties of the drug substance must be investigated and characterized. This scientific approach is referred to as Preformulation studies.

Read more



Services & Solutions

Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T-Cell Therapy Development

March 19, 2025

Porton Advanced is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T-cell therapies for both solid tumors and hematologic malignancies.

Following the successful technology establishment, Porton Advanced will continue to support Eureka's Investigator-Initiated Trials (IITs) by providing CAR-T manufacturing services that adhere to stringent quality standards. These studies, supported by Porton Advanced's end-to-end CDMO platform, are designed to generate critical data for subsequent clinical milestones to further advance Eureka's innovative T-cell therapies.

Porton Advanced has an extensive track record, cumulatively supporting over 60 ATMP Clinical, IND, and IIT projects in China, with orders exceeding 140 IIT batches and maintaining a flawless release success rate for all completed batches. This record highlights the company's consistent capability to meet high-quality manufacturing standards. Porton Advanced will use all the resources, experience, and skills at the company's disposal to ensure the success of Porton Advanced's collaboration with Eureka.

Read more

Porton Advanced Supports Immunofoco's Second IND Clearance from China's CDE for EpCAM CAR-T Therapy in Solid Tumors

March 21, 2025

Porton Advanced is delighted to congratulate our partner, Immunofoco, on receiving clearance from the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) in China for its second Investigational New Drug (IND) application, with the acceptance number CXSL2400901.

Previously, IMC001 obtained IND approvals in both China and the United States in February 2024 for the treatment of EpCAM-positive advanced gastrointestinal tumors.

As Immunofoco's trusted CDMO partner, Porton Advanced provided comprehensive services for this project, including CAR-T cell process development, GMP manufacturing, and production of samples for Investigator-Initiated Trials (IIT). Additionally, we successfully executed site transfer and comparability studies, ensuring seamless technology transition. Notably, the entire process development phase was completed in under four months, followed by first-time-right success in process transfer, scale-up production, and IIT batch manufacturing – all batches met stringent cell quality standards.

Read more

Company Events

Porton Wins Outsourced Pharma 2025 CDMO Leadership Award

March 7, 2025

In March 2025, Porton Pharma Solutions Ltd. was presented with the prestigious "Global Small Molecule API Excellence Award" at the 14th Outsourced Pharma CDMO Leadership Summit, a testament to its comprehensive end-to-end capabilities spanning the entire drug development continuum—from discovery and manufacturing to commercialization.

Commemorating the company's 20th anniversary, this accolade underscores Porton's sustained technical innovation in small molecule active pharmaceutical ingredient (API) and drug product development, while reinforcing its position as a premier global CDMO partner through fully integrated service offerings.

By leveraging cutting-edge platforms and quality-by-design methodologies, Porton continues to deliver robust solutions that accelerate pharmaceutical innovation worldwide.



Read more

Porton's 2024 Annual Report Released

March 29, 2025

In 2024, we undertook a comprehensive management reassessment, navigating pressures and challenges with unwavering resolve while maintaining our commitment to continuous improvement. We advanced initiatives aligned with our four strategic pillars established at the start of the year: enhancing market expansion and order capture capabilities, driving cost optimization and efficiency improvements, strengthening governance and operational excellence of overseas subsidiaries, and leveraging ESG frameworks to foster sustainable growth.

Read more

ESG

Porton's Near-Term Target Validated by the SBTi

March 20, 2025

March 20, 2025， Porton Pharma Solutions announced that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi).

This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.

Read more

Porton's 2024 ESG Report Released

March 31, 2025

Porton is committed to integrating sustainable development into its daily management and operations. Guided by its ESG concept of "Green Development, Promote Common Progress, Build a Healthy Society Together, and Enhance Corporate Governance," Porton continuously advances ESG management enhancements, actively addresses stakeholder concerns, strengthens material topics and key performance management, and supports the achievement of the United Nations Sustainable Development Goals (UN SDGs) through concrete actions.

Moving forward, we remain steadfast in our mission, enabling the public's access to good medicines, and look forward to collaborating with partners worldwide to advance global sustainable development.

Read more

Marketing Activities

Previous Events

2025 IBI EXPO
March 1-2
Suzhou China

The 9th Annual FTD Forum
March 14
San Diego

DCAT Week 2025
March 17-20
New York

ACS San Diego
March 26-27
San Diego

World ADC London
March 3-6
London UK

Bio-Europe Spring 2025
March 17-19
Milan Italy

2025 CMAC
March 18-20
Suzhou China

Upcoming Events

Stay Updated on the Latest Developments, Click to Schedule Your Appointment

Events	Date	Venue	Booth
CPHI Japan 2025	April 9-11	Tokyo, Japan	5Q-18
Applied Pharmaceutical Chemistry 2025	April 10	Boston MA, United States	/
20th Annual Garnet E. Peck Symposium	April 10	West Lafayette, IN, United States	/
11 STILLE	April 26	Colorado State University, United States	/
Swiss Biotech Day	May 5-6	Basel, Switzerland	/
2nd ADC Linker & Conjugation Summit	May 6-8	Boston MA, United States	/
BIO Korea 2025	May 7-9	Seoul, Korea	J30
ASGCT Annual Meeting	May 13-17	Portland, United States	1448
Boston ABI Lab Lunch and Learn	May 15	Natick MA, United States	/
The Fifth China Gene & Cell Therapy Innovation Forum (CGCT 2025)	May 16-17	Shenzhen, China	/
CPhI Americas 2025	May 20-22	Pennsylvania Convention Center, Philadelphia, United States	405
API China 2025	May 21-23	Guangzhou, China	10.3H05

Customized Development and Manufacturing

Technical Solutions for Conventional and New Drug Modalities

OEB 1 to 5 | Sub-g to Metric-ton Scale | Pre-clinical to Commercial

- Small Molecules
- Tides
- Biologics and Conjugates
- Advanced Therapy Medicinal Products

Operational Excellence	IP · QA · EHS · RA · PM · Supply Chain
Global Site Compliance	FDA U.S. FOOD & DRUG ADMINISTRATION · World Health Organization · EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH · Pmda · 国家药品监督管理局 National Medical Products Administration

PORTON

A Customer Centric, Innovative, and Reliable CDMO with Global Solutions

Please contact us to help you on your next development project and achieve your business goals.

LinkedIn
Porton Pharma Solutions

business@portonpharma.com
www.portonpharma.com

Contact Us